, GlaxoSmithKline, London, United Kingdom

• Drugs and Therapy Studies Vol. 2 No. 1 (2012) - Original Articles
  Impact of HIV subtype on response and resistance in antiretroviral-naïve adults comparing treatment with once daily versus twice daily ritonavir boosted fosamprenavir in combination with Abacavir/Lamivudine
  Abstract  PDF